Mark Wildgust, Vice President of Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared on X:
“At ESMO26 we introduced a new word, RIPTAC, JNJ-6143.
Introducing another innovation presented Society for Immunotherapy of Cancer yesterday!
FIH Investigational combo of Pasritamig our J&J Innovative Medicine KLK2xCD3 T-cell agent + our PSMA x CD28 co-stim JNJ-9401. Signal 1 and signal 2 together!”
You can also read:
Mark Wildgust: ESMO26 Highlights JNJ-6143’s First-in-Class Approach to Targeting Prostate Cancer
